60644345-255f-4313-b2b1-ea76f686146e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- APICAL_SURFACE+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- ESTROGEN_RESPONSE_LATE+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- KRAS_SIGNALING_UP+0.300
- P53_PATHWAY+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.300
- HEDGEHOG_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PROTEIN_SECRETION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MITOTIC_SPINDLE-0.200
- ADIPOGENESIS-0.100
- APOPTOSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR600724 | GTEX | — | 0.787 |
| 2 | SRR1084484 | GTEX | — | 0.786 |
| 3 | SRR10900019 | — | — | 0.784 |
| 4 | SRR1093773 | GTEX | — | 0.779 |
| 5 | 22f63ce0-5364-48b0-b424-5b971a1dcd33 | — | — | 0.773 |
| 6 | SRR1465632 | GTEX | — | 0.767 |
| 7 | SRR1099023 | GTEX | — | 0.767 |
| 8 | SRR1078347 | GTEX | — | 0.766 |
| 9 | SRR1498482 | GTEX | — | 0.763 |
| 10 | SRR1341898 | GTEX | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |